Grant: Engage Grants Program
University of Guelph
$24,768.00
Mapping interactions between Phytoglycogen and bioactive compounds for biotechnological**applications
FY 2018-19
Summary
Mirexus Biotechnologies Inc. is an emerging Canadian company specializing in the development of novel*natural biomaterials for applications in personal care, nutrition and biomedicine. The company's proprietary*biomaterial phytoglycogen, a natural polysaccharide extracted from sweet corn, is produced as monodisperse,*biodegradable and non-toxic nanoparticle, and is safe for human use.*Due to its excellent biocompatibility and the principal capability to encapsulate small molecules,*phytoglycogen is considered an attractive platform for the development of novel delivery systems for*nutraceutically, cosmetically and pharmacologically active compounds which are poorly soluble, or cannot*transverse cell membranes on their own.*Fundamental understanding of the features of phytoglycogen that allow it to bind and carry other molecules is*essential for the development of efficient delivery systems. To assist Mirexus with the development of new*generation of products, a research team led by Professor Vladimir Ladizhansky proposes to use a method of*Nuclear Magnetic Resonance and design special screening tests that would be able to quickly determine how*strongly the target molecules interact with phytoglycogen, and further identify molecular and structural motifs*that promote interactions with phytoglycogen.*The knowledge and methodologies designed in this project would be an essential step in creating new*products. It would allow the company to focus on the development of new specific active compounds that are*more likely to interact with phytoglycogen, or to develop phytoglycogen derivatives which can interact with a*wider spectrum of bioactive compounds. Mirexus is currently building a new manufacturing facility in Guelph;*in additional to obvious benefits to health and well-being, the development of new products would help create*new jobs in both R&D and production.
Program
Engage Grants Program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
523519-2018
Name nom
Ladizhansky, Vladimir
Department département
Physics
Organization id
24
Institution établissement
University of Guelph
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
24768
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
3500
Research subject group en
Analytical chemistry
Research subject group fr
Chimie analytique
Research subject en
Analytical chemistry
Research subject fr
Chimie analytique
Partie
1
Nb partie
1
Application title
Mapping interactions between Phytoglycogen and bioactive compounds for biotechnological**applications
Keyword
NSERC
Application summary
Mirexus Biotechnologies Inc. is an emerging Canadian company specializing in the development of novel*natural biomaterials for applications in personal care, nutrition and biomedicine. The company's proprietary*biomaterial phytoglycogen, a natural polysaccharide extracted from sweet corn, is produced as monodisperse,*biodegradable and non-toxic nanoparticle, and is safe for human use.*Due to its excellent biocompatibility and the principal capability to encapsulate small molecules,*phytoglycogen is considered an attractive platform for the development of novel delivery systems for*nutraceutically, cosmetically and pharmacologically active compounds which are poorly soluble, or cannot*transverse cell membranes on their own.*Fundamental understanding of the features of phytoglycogen that allow it to bind and carry other molecules is*essential for the development of efficient delivery systems. To assist Mirexus with the development of new*generation of products, a research team led by Professor Vladimir Ladizhansky proposes to use a method of*Nuclear Magnetic Resonance and design special screening tests that would be able to quickly determine how*strongly the target molecules interact with phytoglycogen, and further identify molecular and structural motifs*that promote interactions with phytoglycogen.*The knowledge and methodologies designed in this project would be an essential step in creating new*products. It would allow the company to focus on the development of new specific active compounds that are*more likely to interact with phytoglycogen, or to develop phytoglycogen derivatives which can interact with a*wider spectrum of bioactive compounds. Mirexus is currently building a new manufacturing facility in Guelph;*in additional to obvious benefits to health and well-being, the development of new products would help create*new jobs in both R&D and production.